| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SCAP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SCAP抗体的3篇参考文献的简要信息，涵盖其应用场景及研究背景：
---
1. **文献名称**：*Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein*
**作者**：Yang, T., Espenshade, P.J., Wright, M.E., Yabe, D., Gong, Y., et al.
**摘要**：该研究通过开发特异性SCAP抗体，发现CHO细胞中胆固醇调控缺陷与SCAP蛋白的D443N突变相关。抗体用于免疫印迹验证突变SCAP的表达及功能异常，揭示了SCAP在SREBP通路中的关键作用。
2. **文献名称**：*Insig-dependent ubiquitination and degradation of mammalian SCAP in sterol-replete cells*
**作者**：Gong, Y., Lee, J.N., Lee, P.C., Goldstein, J.L., Brown, M.S., et al.
**摘要**：作者利用SCAP多克隆抗体追踪其在固醇充足条件下的降解机制。研究发现Insig蛋白介导SCAP的泛素化，抗体在共沉淀实验和免疫荧光中证实了SCAP-Insig复合物的动态互作。
3. **文献名称**：*Hepatic SCAP overexpression exacerbates atherosclerosis in LDL receptor-deficient mice*
**作者**：Horton, J.D., Shah, N.A., Warrington, J.A., et al.
**摘要**：通过构建肝脏特异性SCAP过表达小鼠模型，结合SCAP抗体的免疫组化分析，证明SCAP上调促进SREBP-1激活，加剧脂质代谢紊乱和动脉粥样硬化，为代谢疾病治疗提供靶点依据。
---
**说明**：以上文献聚焦SCAP抗体在机制研究(如突变检测、蛋白互作)及疾病模型(如动脉粥样硬化)中的应用，经典研究多来自胆固醇代谢领域的权威团队(如Goldstein/Brown实验室)。实际引用时建议通过PubMed或期刊官网核对具体卷期页码。
SCAP (SREBP Cleavage-Activating Protein) is a key regulatory protein in cholesterol and lipid metabolism. It functions as a sterol sensor and chaperone for sterol regulatory element-binding proteins (SREBPs), transcription factors that control genes involved in cholesterol synthesis and uptake. Under low cellular cholesterol conditions, SCAP escorts SREBPs from the endoplasmic reticulum (ER) to the Golgi apparatus, where SREBPs undergo proteolytic activation. Activated SREBPs then migrate to the nucleus to upregulate lipid biosynthesis genes. When cholesterol levels are sufficient, SCAP retains SREBPs in the ER by binding to insulin-induced gene (Insig) proteins, inhibiting further lipid production.
SCAP antibodies are essential tools for studying cholesterol homeostasis, metabolic disorders, and related diseases like atherosclerosis or obesity. They enable detection of SCAP expression, localization, and protein interactions via techniques such as Western blotting, immunofluorescence, or co-immunoprecipitation. Research using these antibodies has elucidated SCAP’s conformational changes during sterol sensing and its role in pathologies linked to dysregulated lipid metabolism. Additionally, SCAP-targeting therapeutic strategies, including small-molecule inhibitors, are being explored to modulate cholesterol levels, highlighting the protein’s clinical relevance. Understanding SCAP dynamics through antibody-based assays continues to advance insights into metabolic regulation and potential treatments for cardiovascular and metabolic diseases.
×
